[go: up one dir, main page]

PE20141380A1 - Imidazopiridazinas como inhibidores de quinasa akt - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt

Info

Publication number
PE20141380A1
PE20141380A1 PE2013002192A PE2013002192A PE20141380A1 PE 20141380 A1 PE20141380 A1 PE 20141380A1 PE 2013002192 A PE2013002192 A PE 2013002192A PE 2013002192 A PE2013002192 A PE 2013002192A PE 20141380 A1 PE20141380 A1 PE 20141380A1
Authority
PE
Peru
Prior art keywords
compounds
halogen
cyane
hydroxy
alkyl
Prior art date
Application number
PE2013002192A
Other languages
English (en)
Inventor
Lars Barfacker
William Johnston Scott
Andrea Hagebarth
Stuart Ince
Harmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bomer
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of PE20141380A1 publication Critical patent/PE20141380A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE: R1 ES H, HIDROXI, HALOGENO, CIANO, C(O)(ALQUILO C1-6), ENTRE OTROS; R2 ES H, HIDROXI, HALOGENO, CIANO, NHC(O)(ALQUILO C1-6), ENTRE OTROS; R3 ES H, HIDROXI, C(O)(ALQUILO C1-6), CIANO, HALOGENO, ENTRE OTROS; R4 ES FENILO OPCIONALMENTE SUSTITUIDO UNA, DOS O TRES VECES, EN FORMA IDENTICA O DIFERENTE, CON UN ATOMO DE HALOGENO; X E Y ES CH2; n ES 0,1,2. SON COMPUESTOS PREFERIDOS: 1-[4-(6-METIL-3-FENILIMIDAZO[1,2-b]PIRIDAZIN-2-IL)FENIL]-CICLOBUTAMINA; ACIDO 2-[4-(1-AMINOCICLOBUTIL)FENIL]-3-FENILIMIDAZO[1,2-b]-PIRIDAZIN-6-CARBOXILICO; ENTRE OTROS.SE REFIERE TAMBIEN A UN PROCESO PARA PARA LA FABRICACION DE DICHOS COMPUESTOS Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE CANCER DE MAMAS
PE2013002192A 2011-04-07 2012-04-05 Imidazopiridazinas como inhibidores de quinasa akt PE20141380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07

Publications (1)

Publication Number Publication Date
PE20141380A1 true PE20141380A1 (es) 2014-10-18

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002192A PE20141380A1 (es) 2011-04-07 2012-04-05 Imidazopiridazinas como inhibidores de quinasa akt

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629927T3 (es) 2008-06-16 2017-08-16 University Of Tennessee Research Foundation Compuesto para el tratamiento del cáncer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
BR112013025777A2 (pt) * 2011-04-07 2016-12-20 Bayer Ip Gmbh imidazopiridazinas como inibidores da quinase akt
CA2860724A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
US9260435B2 (en) * 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
AU2014225761B2 (en) 2013-03-05 2018-06-07 University Of Tennessee Research Foundation Compounds for treatment of cancer
US20150352121A1 (en) * 2013-03-12 2015-12-10 Glaxosmithkline Llc Combination
WO2014153001A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Combination therapy for treating cancer
WO2015104254A1 (en) * 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
KR102611539B1 (ko) * 2016-11-28 2023-12-06 브리스톨-마이어스 스큅 컴퍼니 Gsk-3 억제제
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782971B2 (en) 1999-12-23 2005-09-15 Nicox S.A. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
DE60128211T2 (de) 2000-03-31 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituierte imidazopyridine
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7579355B2 (en) 2003-04-24 2009-08-25 Merck & Co., Inc. Inhibitors of Akt activity
KR20060034303A (ko) 2003-07-30 2006-04-21 라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이. 암을 예방하고 치료하기 위한 치환된 이미다조피리미딘
US7655649B2 (en) 2004-04-09 2010-02-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
WO2006021303A1 (de) 2004-08-24 2006-03-02 Basf Aktiengesellschaft Imidazolium-methylsulfite als ausgangsverbindungen zur herstellung ionischer flüssigkeiten
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Akt活性のインヒビター
EP1902056A2 (en) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
BRPI0611717A2 (pt) 2005-06-10 2009-01-13 Merck & Co Inc composto, composiÇço farmacÊutica e uso do composto
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
AU2008262038A1 (en) * 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
PA8793201A1 (es) 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Pirimidinas bicíclicas fusinadas
JP5327652B2 (ja) * 2007-08-14 2013-10-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 癌処理のための融合されたイミダゾール
US20100331333A1 (en) 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2009255358A1 (en) 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
EP2391623A4 (en) 2009-02-02 2012-09-05 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
EA201101186A1 (ru) * 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (en) * 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
WO2012007345A2 (en) * 2010-07-12 2012-01-19 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrimidines and -pyridines
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−b]ピリダジン
BR112013025777A2 (pt) * 2011-04-07 2016-12-20 Bayer Ip Gmbh imidazopiridazinas como inibidores da quinase akt

Also Published As

Publication number Publication date
EA024890B1 (ru) 2016-10-31
WO2012136776A1 (en) 2012-10-11
BR112013025777A2 (pt) 2016-12-20
GT201300238A (es) 2015-04-06
CO6862145A2 (es) 2014-02-10
JP2014510127A (ja) 2014-04-24
AU2012238589B2 (en) 2017-02-16
DOP2013000226A (es) 2013-11-15
KR20140022057A (ko) 2014-02-21
CU20130135A7 (es) 2014-02-28
PT2694510E (pt) 2016-02-08
CA2832374A1 (en) 2012-10-11
HRP20160011T1 (hr) 2016-02-12
MX336865B (es) 2016-02-04
EP2694510B1 (en) 2015-10-14
TWI535719B (zh) 2016-06-01
UY34006A (es) 2012-10-31
JP5906303B2 (ja) 2016-04-20
TN2013000400A1 (en) 2015-03-30
US9604989B2 (en) 2017-03-28
CY1117163T1 (el) 2017-04-05
AU2012238589A1 (en) 2013-11-07
NI201300105A (es) 2014-07-14
CU24263B1 (es) 2017-07-04
ME02316B (me) 2016-06-20
MA35016B1 (fr) 2014-04-03
SI2694510T1 (sl) 2016-02-29
TW201245204A (en) 2012-11-16
US20150368250A1 (en) 2015-12-24
US9206185B2 (en) 2015-12-08
ZA201307223B (en) 2014-12-23
CL2013002878A1 (es) 2014-05-02
EA201301130A1 (ru) 2014-07-30
AP3597A (en) 2016-02-19
EP2694510A1 (en) 2014-02-12
US20140113901A1 (en) 2014-04-24
DK2694510T3 (en) 2016-01-18
SMT201600001B (it) 2016-02-25
PL2694510T3 (pl) 2016-03-31
JO3068B1 (ar) 2017-03-15
IL228567A0 (en) 2013-12-31
CN103596957B (zh) 2016-12-07
UA111739C2 (uk) 2016-06-10
MX2013011699A (es) 2014-01-31
HUE026323T2 (en) 2016-05-30
CR20130515A (es) 2013-12-04
ECSP13013008A (es) 2013-12-31
NZ616270A (en) 2015-09-25
RS54480B1 (en) 2016-06-30
SG193631A1 (en) 2013-11-29
PH12013502073A1 (en) 2014-01-13
CN103596957A (zh) 2014-02-19
ES2558780T3 (es) 2016-02-08
AP2013007215A0 (en) 2013-10-31
AR087148A1 (es) 2014-02-26

Similar Documents

Publication Publication Date Title
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CR20170367A (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
PE20171338A1 (es) Compuestos y composiciones como inhibidores de quinasa raf
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
AR095347A1 (es) Compuestos orgánicos
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
PE20141120A1 (es) Compuestos heterociclicos
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UY32848A (es) Compuestos heterocíclicos de oxima
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.

Legal Events

Date Code Title Description
FC Refusal